0.7B (+65% Y/Y, US $5.0B +41%); Zepbound US revenue $5.35B (+48% Y/Y); non-GAAP diluted EPS $7.48 (+7%); GAAP diluted EPS $7.22 (+16%) — both include $4.57 per-share acquired IPR&D charge from AtaiBeckley and Curevo deals; operating income $8.6B (+17% Y/Y); Key Products revenue 7.1B; raises full-year 2026 revenue guide to $91–$92B (from $85–$87B, prior consensus ~$88B) and tightens non-GAAP EPS guide to $35.00–$36.00 (from $35.50–$36.50 as the $4.57 Q3 IPR&D offsets a $4.07 midpoint underlying raise); health-care sector was the day's leader with LLY lifting XLV to a record close" /> 0.7B (+65% Y/Y, US $5.0B +41%); Zepbound US revenue $5.35B (+48% Y/Y); non-GAAP diluted EPS $7.48 (+7%); GAAP diluted EPS $7.22 (+16%) — both include $4.57 per-share acquired IPR&D charge from AtaiBeckley and Curevo deals; operating income $8.6B (+17% Y/Y); Key Products revenue 7.1B; raises full-year 2026 revenue guide to $91–$92B (from $85–$87B, prior consensus ~$88B) and tightens non-GAAP EPS guide to $35.00–$36.00 (from $35.50–$36.50 as the $4.57 Q3 IPR&D offsets a $4.07 midpoint underlying raise); health-care sector was the day's leader with LLY lifting XLV to a record close" />